Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease

Table 5

Change in calcium × phosphorus product levels.

Reference	Paricalcitol group	Placebo group	𝑃 value
	𝑛/𝑁	𝑛/𝑁
Abboud et al. [8] (QD)	5/35	2/39	0.245
Abboud et al. [8] (TIW)	8/69	5/71	0.396
Coyne et al. [9]	13/101	7/108	0.161